Binergia

The Russian pharmaceutical The Binergia company for January 2021 is engaged in the development, registration, production and launch on the market of drugs intended for the provision of inpatient and outpatient medical care. The main activity of the company is the registration and production of anesthetic drugs.

The research center of the company, in close cooperation with Russian institutes, is engaged in the development of technological processes for the production of medicines, organizes preclinical and clinical studies, validates analysis methods, studies the stability of accumulated samples of substances and drugs, and draws up packages of documents for state registration. As of January 2021, Binergia produces more than 20 drugs and substances.

History

2023: Construction of a factory for the production of drugs in cartridges and ampoules for 4 billion rubles

In the urban district of Chernogolovka, Moscow Region, a plant for the production of drugs in cartridges and ampoules is being built. The developer is Favorite Trade JSC, which is part of the Binergia group of companies. The activities of the latter are related to the development of drugs, including anesthetics, according to the company's website.

According to Binergia's own data, the group by August 2023 is the first and only manufacturer of anesthetics in cartridges in Russia. This form of production is highly in demand in dentistry and in the production of disposable syringes.

A factory for the production of drugs in cartridges and ampoules is being built in the urban district of Chernogolovka

On August 30, 2023, Glavgosstroynadzor of the Moscow Region announced an inspection at the construction of a drug production plant with a finished product warehouse in Chernogolovka. A three-story building with an area of ​ ​ more than 12 thousand sq.m. began to be built at the end of the summer of 2022. By the end of August 2023, builders are mounting the facade, underground and above-ground structures of the building are made. They plan to complete the facility in the third quarter of 2024.

The project involves the construction of a building for the production of medicines, including hormonal drugs, quality control laboratories, administrative and household premises, a warehouse for storing finished products, raw materials and packaging materials. The basis of the production line will be nosology drugs.

The annual capacity of injection solutions will be able to reach 50 million cartridges and 4 million ampoules, up to 4 million solutions in glass and plastic vials, as well as 3 million suspensions in ampoules and 1 million in vials. The company will create 289 jobs, according to the Main Directorate of State Construction Supervision of the Moscow Region. As previously reported, the volume of investments is about 4 billion rubles.^[1]

Notes